v3.26.1
Restatement of Previously Issued Financial Statements - Schedule of Restated Consolidated Statement of Cash Flows (Details) - USD ($)
$ in Thousands
 3 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities    
Consolidated net loss $ (8) $ (21)
Change in fair value of warrant liability 1,810 25,965
Inventory (583) (188)
Prepaid expenses and other current assets 105 (20)
Deferred revenue 186
Other non-cash expenses (1,217) 73
Depreciation and amortization 377 281
Stock-based compensation 8,202
Net cash used by operating activities (1,610) (2,358)
Cash flows from investing activities    
Purchase of property and equipment (71) (138)
Proceeds from maturities and sales of short-term investments 2,116
Net cash used in investing activities (124,189) (440)
Contributions from non-controlling interests 4
Proceeds from issuance of shares of common stock 69,066 8,063
Net cash used in financing activities 78,248 8,059
Net change in cash and cash equivalents (47,551) 5,261
Cash and cash equivalents at beginning of the period 185,574 14,566
Cash and cash equivalents at end of the period 138,023 19,827
As Previously Reported [Member]    
Cash flows from operating activities    
Consolidated net loss [1] (8,402) (3,548)
Change in fair value of warrant liability
Inventory (498) (248)
Prepaid expenses and other current assets [1] 107  
Deferred revenue 110  
Other non-cash expenses [1]  
Depreciation and amortization 353 513
Stock-based compensation 8,284
Net cash used by operating activities [1] (1,605) (3,578)
Cash flows from investing activities    
Purchase of property and equipment (454) (78)
Proceeds from maturities and sales of short-term investments [1] 2,079  
Net cash used in investing activities [1] 1,540 (380)
Contributions from non-controlling interests [1]   (21)
Proceeds from issuance of shares of common stock 69,065 [1] 9,244
Net cash used in financing activities [1] 78,247 9,219
Net change in cash and cash equivalents 78,182  
Cash and cash equivalents at beginning of the period 193,629  
Cash and cash equivalents at end of the period 271,811  
Restatement Adjustment [Member]    
Cash flows from operating activities    
Consolidated net loss [1] (1,751) (26,017)
Change in fair value of warrant liability 1,810 25,965
Inventory (85) 60
Prepaid expenses and other current assets [1] (2)  
Deferred revenue 76  
Other non-cash expenses [1] 5  
Depreciation and amortization 24 (232)
Stock-based compensation (82) 1,444
Net cash used by operating activities [1] (5) 1,220
Cash flows from investing activities    
Purchase of property and equipment (125,766) (60)
Proceeds from maturities and sales of short-term investments [1] 37  
Net cash used in investing activities [1] (125,729) (60)
Contributions from non-controlling interests [1]   21
Proceeds from issuance of shares of common stock 1 [1] (1,181)
Net cash used in financing activities [1] 1 (1,160)
Net change in cash and cash equivalents (125,733)  
Cash and cash equivalents at beginning of the period (8,055)  
Cash and cash equivalents at end of the period (133,788)  
As Restated [Member]    
Cash flows from operating activities    
Consolidated net loss [1] (10,153) (29,565)
Change in fair value of warrant liability 1,810 25,965
Inventory (583) (188)
Prepaid expenses and other current assets [1] 105  
Deferred revenue 186  
Other non-cash expenses [1] (1,217)  
Depreciation and amortization 377 281
Stock-based compensation 8,202 1,444
Net cash used by operating activities [1] (1,610) (2,358)
Cash flows from investing activities    
Purchase of property and equipment (126,220) (138)
Proceeds from maturities and sales of short-term investments [1] 2,116  
Net cash used in investing activities [1] (124,189) (440)
Contributions from non-controlling interests [1]  
Proceeds from issuance of shares of common stock 69,066 [1] 8,063
Net cash used in financing activities [1] 78,248 $ 8,059
Net change in cash and cash equivalents (47,551)  
Cash and cash equivalents at beginning of the period 185,574  
Cash and cash equivalents at end of the period $ 138,023  
[1] Represents the downstream effects of the identified restatement adjustments and other individually immaterial changes.